Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;7(11):762-766.
doi: 10.1002/sctm.18-0074. Epub 2018 Sep 25.

Cell-Based Therapies: The Nonresponder

Arnold I Caplan  1
Affiliations

Cell-Based Therapies: The Nonresponder

Arnold I Caplan. Stem Cells Transl Med. 2018 Nov.

Abstract

Cell-based therapies have come of age and several phase III trials are now being conducted. Cell-based therapies, especially involving mesenchymal stem cells (MSCs), have substantial nonresponder rates, as has been reported in some current clinical trials. This high rate is expected as the MSCs are neither tuned for each of the diseases that are being treated nor for the huge variance in the genetics and response characteristics of the individual patients being treated. Such nonresponders might be used as a control group, thus eliminating the need for placebo controls. Stem Cells Translational Medicine 2018;7:762-766.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. American Association of Blood Banks . Highlights of Transfusion Medicine History. Available at http://www.aabb.org/tm/Pages/highlights.aspx. Accessed August 14, 2018.
    1. Park B, Yoo KH, Kim C. Hematopoietic stem cell expansion and generation: the ways to make a breakthrough. Blood Res 2015;50:194–203. - PMC - PubMed
    1. Chinen Y, Higa T, Tomatsu S et al. Long‐term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA. Mol Genet Metab Rep 2014;1:31–41. - PMC - PubMed
    1. St Bernard R, Chodirker L, Masih‐Khan E et al. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis‐dependent renal failure. Bone Marrow Transplant 2015;50:95–99. - PubMed
    1. Mesoblast . Mesoblast receives TGA regulatory approval to commercially manufacture adult stem cell products. Australia: Mesoblast Limited, 2010.

Publication types

MeSH terms